Repare Therapeutics (NASDAQ:RPTX - Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.
Repare Therapeutics Stock Performance
RPTX stock traded down $0.03 on Friday, reaching $1.29. The company's stock had a trading volume of 138,460 shares, compared to its average volume of 225,964. The business has a fifty day simple moving average of $1.28 and a two-hundred day simple moving average of $2.55. Repare Therapeutics has a 12-month low of $1.10 and a 12-month high of $7.45. The firm has a market cap of $54.84 million, a PE ratio of -0.65 and a beta of 0.88.
Wall Street Analyst Weigh In
Several brokerages have commented on RPTX. Lifesci Capital reissued a "market perform" rating on shares of Repare Therapeutics in a research report on Friday, December 13th. Stifel Nicolaus lowered their price objective on Repare Therapeutics from $9.00 to $4.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Bloom Burton lowered Repare Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 10th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Repare Therapeutics in a research report on Friday, November 8th.
Check Out Our Latest Analysis on RPTX
Repare Therapeutics Company Profile
(
Get Free Report)
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
Read More
Before you consider Repare Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repare Therapeutics wasn't on the list.
While Repare Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
